# Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

> **NCT01258933** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT01258933
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07-06
- **Primary completion:** 2024-10-18
- **Final completion:** 2024-10-18
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258933, "Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01258933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*